



Medicaid Fee- for- Service Providers
Dispense Brand Name Drug when Less Expensive than Generic Program
REVISED

Effective 05/26/2016, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Imitrex Kit (pens and Cartridges) will be added to the program.
Ability Tablets*, Cymbalta and Renvela Tablets will be removed from the program.
*Ability Solution remains in the program

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
Have a generic copayment.
Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program do not require the submission of Dispense as Written/Product Selection Code of '1'; Pharmacies can submit any valid NCPDP field (408-D8) value.

List of Brand Name Drugs included in this program* (Updated): 05/16/2016

Table with 3 columns: Drug Name, Strength/Dosage, and Brand Name. Includes drugs like Ability Solution, Adderall XR, Aggrenox, Aldara, Alphagan P 0.15%, Astepro, Baraclude, Catapres-TTS, Cellcept suspension, Combivir, Copaxone 20ml SQ, Diastat, Eпивir HBV tablet, Exelon Patch, Focalin XR, Gabitril, Gleevec, Hepsera, Imitrex Kit, Kapvay, Mepron, Myfortic, Nasonex, Niaspan, Patanase, Protopic, Pulmicort Respules, Soriatane, Tegretol suspension, Tegretol XR, Tobradex suspension, Trilipix, Trizivir, Valcyte, Voltaren Gel, Xeloda, Xenazine.

*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.